司库奇尤单抗在清除皮损和改善生活质量方面持续优于乌司奴单抗:CLARITY 3b期双盲试验52周结果
CLARITY(NCT02826603)是一项3b期双盲试验,中重度斑块状银屑病患者随机接受司库奇尤单抗300 mg(n=550)或乌司奴单抗45/90 mg(n=552)治疗。52周时,司库奇尤单抗在PASI 90应答率(73.2% vs 59.8%)、IGA 0/1应答率(76.0% vs 60.2%)和DLQI 0/1应答率(69.9% vs 61.2%)方面均优于乌司奴单抗,不良事件发生率两组相当。
要点
- 52周时司库奇尤单抗PASI 90应答率73.2%,显著高于乌司奴单抗的59.8%。
- IGA 0/1应答率司库奇尤单抗76.0%,乌司奴单抗60.2%,差异显著。
- DLQI 0/1应答率司库奇尤单抗69.9%,乌司奴单抗61.2%,司库奇尤单抗更优。
核心结论
- CLARITY研究52周结果显示,司库奇尤单抗在皮损清除和生活质量改善方面持续优于乌司奴单抗,安全性与此前试验相当。
研究设计与样本
- CLARITY(NCT02826603)是一项3b期双盲研究,中重度斑块状银屑病患者随机接受司库奇尤单抗300 mg(n=550)或乌司奴单抗45/90 mg(n=552)治疗。
主要发现
- 52周时,司库奇尤单抗组PASI 90应答率为73.2%,乌司奴单抗组为59.8%(OR 1.84,95%CI 1.41-2.41;P<0.0001)。
- 52周时,司库奇尤单抗组IGA 0/1应答率为76.0%,乌司奴单抗组为60.2%(OR 2.12,95%CI 1.61-2.79;P<0.0001)。
- 52周时,司库奇尤单抗组DLQI 0/1应答率为69.9%,乌司奴单抗组为61.2%(P=0.0028)。
- 两组任何不良事件的发生率相当。
关键数值与推荐
- PASI 90应答率:司库奇尤单抗73.2% vs 乌司奴单抗59.8%(OR 1.84,95%CI 1.41-2.41;P<0.0001)。
- IGA mod 2011 0/1应答率:司库奇尤单抗76.0% vs 乌司奴单抗60.2%(OR 2.12,95%CI 1.61-2.79;P<0.0001)。
- DLQI 0/1应答率:司库奇尤单抗69.9% vs 乌司奴单抗61.2%(P=0.0028)。
临床怎么用
- 对于中重度斑块状银屑病,司库奇尤单抗在52周内的皮损清除和生活质量改善方面优于乌司奴单抗。
- 司库奇尤单抗与乌司奴单抗的安全性相当,选择治疗方案时可参考此头对头比较数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secukinumab demonstrated superior efficacy over ustekinumab in the treatment of moderate to severe plaque psoriasis over 16 weeks in the CLARITY study and over 52 weeks in the CLEAR study. OBJECTIVE: To compare the efficacy and safety of secukinumab vs. ustekinumab over 52 weeks in CLARITY. METHODS: Analysis of 52-week data from CLARITY (NCT02826603), a phase 3b study in which patients were randomized to receive secukinumab 300 mg (n = 550) or ustekinumab 45/90 mg (n = 552) per label. RESULTS: At week 52, secukinumab was superior to ustekinumab in the proportion of patients who achieved ≥ 90% improvement in Psoriasis Area and Severity Index (73.2% vs. 59.8%; odds ratio [OR], 1.84 [95% CI, 1.41-2.41]; P < 0.0001), Investigator's Global Assessment modified 2011 responses of clear (0) or almost clear (1) skin (76.0% vs. 60.2%; OR, 2.12 [95% CI, 1.61-2.79]; P < 0.0001) and Dermatology Life Quality Index response of no effect (0/1) (69.9% vs. 61.2%; P = 0.0028). Proportions of patients with any adverse events were comparable between treatment arms. CONCLUSIONS: This second head-to-head study confirmed the superior efficacy of secukinumab over ustekinumab in skin clearance and quality of life through 52 weeks, with safety comparable to that reported in previous trials. Clinicaltrials.gov identifier: NCT02826603.
引用
- Bagel J, Blauvelt A, Nia J, et al. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). J Eur Acad Dermatol Venereol. 2020. PMID: 32365251. doi:10.1111/jdv.16558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。